An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor

Annals of the American Thoracic Society

Volumn 14, Issue 11, 2017, Pages 1662-1666

  Jennings, Mark T ^a   Dezube, Rebecca ^a   Paranjape, Shruti ^b   West, Natalie E ^a   Hong, Gina ^c   Braun, Andrew ^a   Grant, Jonathan ^d   Merlo, Christian A ^a   Lechtzin, Noah ^a  

^a Harry and Jeannette Weinberg Cancer Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CFTR modulators; Cystic fibrosis; Post marketing study

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; IVACAFTOR PLUS LUMACAFTOR; PROTON PUMP INHIBITOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BURKHOLDERIA CEPACIA COMPLEX; CHEST TIGHTNESS; CHILD; CLINICAL TRIAL; CYSTIC FIBROSIS; DECREASED APPETITE; DIARRHEA; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUTATION; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PSEUDOMONAS PNEUMONIA; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; WHEEZING; DRUG COMBINATION; DRUG EFFECT; GENETICS; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG COMBINATIONS; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; MUTATION; QUINOLONES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85028432868     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201701-058OC     Document Type: Article

References (14)

1. Boyle MP. Adult cystic fibrosis. JAMA 2007;298:1787-1793.
2. Sosnay PR, Raraigh KS, Gibson RL. Molecular genetics of cystic fibrosis transmembrane conductance regulator: Genotype and phenotype. Pediatr Clin North Am 2016;63:585-598.
3. Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2014 annual data report 2015. Bethesda, MD: Cystic Fibrosis Foundation; 2015 [accessed 2017 Mar 3]. Available from: https:// www. cff. org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report. pdf
4. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, et al.; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del cftr. N Engl J Med 2015;373:220-231.
5. Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med 2017;5:107-118.
6. Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group. Lumacaftor/ivacaftor in patients aged 6-11 years with cystic fibrosis and homozygous for F508del-CFTR. Am J Respir Crit Care Med 2017;195:912-920.
7. Glasgow RE, Lichtenstein E, Marcus AC. Why don't we see more translation of health promotion research to practice?: rethinking the efficacy-to-effectiveness transition. Am J Public Health 2003;93: 1261-1267.
8. Jennings MTDR, Hong G, West NE, Braun A, Merlo CA, Lechtzin N. Lumacaftor/ivacaftor: an observational study of outcomes and tolerances in patients with cystic fibrosis [abstract]. Am J Respir Crit Care Med 2016;193:A7790.
9. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
10. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, et al.; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-1343.
11. MedDRA. Introductory guide to meddra version 19. 1. McLean, VA: MedDRA Maintenance and Support Services Organization; 2016 [accessed 2017 Jan 17]. Available from: https://www. meddra. org/ sites/default/files/guidance/file/intguide-19-1-english. pdf
12. StataCorp. Stata statistical software: Release 12. College Station, TX: StataCorp LP. 2011 [accessed 2017 Jan 17]. Available from: http:// www. scirp. org/%28S%28vtj3fa45qm1ean45vvffcz55%29%29/ reference/ReferencesPapers. aspx?ReferenceID=1909771
13. Ahmad DPM, Mills N, Stephen MJ. Real world experience of lumacaftor-ivacaftor at an urban cystic fibrosis center [abstract]. Pediatr Pulmonol 2016;51:205.
14. Taylor TBR, Tolle J. Lumacaftor-ivacaftor tolerance in cystic fibrosis patients homozygous for phe508del CFTR: a single-center observational study [abstract]. Pediatr Pulmonol 2016;51:292.